Online citations, reference lists, and bibliographies.

Pheochromocytoma/Paraganglioma: Update On Diagnosis And Management

I. Jochmanová, K. Pacak
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
After more than a century since they were described, pheochromocytomas and paragangliomas (PHEOs/PGLs) still pose great diagnostic and therapeutic challenges. Recent discoveries and progress in the understanding of molecular and metabolic changes associated with tumorigenesis allowed us to get closer to deciphering the secrets of these tumors. New knowledge allows us to develop novel diagnostic methods and identify specific treatment targets to improve the care of PHEO/PGL patients.
This paper references
10.1210/jc.2012-1958
Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.
V. Hartung-Knemeyer (2012)
10.1210/JC.2004-2025
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.
G. Eisenhofer (2005)
10.1016/j.ejim.2009.08.002
ACTH-producing pheochromocytoma: clinical considerations and concise review of the literature.
M. F. Nijhoff (2009)
10.2169/INTERNALMEDICINE.47.1360
Pheochromocytoma presenting as acute myocarditis with cardiogenic shock in two cases.
Xue-Ming Wu (2008)
10.1210/JC.2003-030262
Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.
J. Mundschenk (2003)
10.1016/j.jvir.2009.01.031
Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers.
M D Mamlouk (2009)
10.2169/internalmedicine.54.4732
Ventricular Rhythm and Hypotension in a Patient with Pheochromocytoma-induced Myocardial Damage and Reverse Takotsubo Cardiomyopathy.
Minoru Tagawa (2015)
10.1007/978-1-62703-697-9_14
Pheochromocytoma Hypertensive Crisis
Vitaly Kantorovich (2014)
10.1038/sj.jhh.1001644
Diurnal blood pressure variationin pheochromocytoma, primary aldosteronism and Cushing's syndrome
T. Zelinka (2004)
[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)].
P. Plouin (1981)
10.1200/JCO.2005.03.6046
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
M. Kulke (2006)
PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma.
B. Shulkin (1992)
10.1016/j.surg.2012.08.023
Utility of oral nicardipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas.
Hasan K. Siddiqi (2012)
10.1210/jcem-49-3-322
Pancreatic α- and β-Cell Function in Pheochromocytoma
M. Hamaji (1979)
10.1161/01.HYP.29.5.1133
Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.
P. Plouin (1997)
10.1111/eci.12245
Clinical utility of chromogranin A in SDHx‐related paragangliomas
Samuel M. Zuber (2014)
10.1096/fj.12-210146
Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function
C. Yang (2012)
10.1097/01.hjh.0000185714.60788.52
Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients
T. Zelinka (2005)
10.1002/cncr.27675
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas
D. Oh (2012)
10.1515/jpem.2010.102
Cushing Syndrome in an Infant Due to Cortisol Secreting Adrenal Pheochromocytoma: A Rare Association
M. Kumar (2010)
10.1002/cncr.23812
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine
H. Huang (2008)
10.1016/j.hoc.2015.09.006
Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.
L. Fishbein (2016)
10.1056/NEJM198109103051107
Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma.
E. Bravo (1981)
10.1016/j.pharmthera.2016.04.009
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.
Caroline Wigerup (2016)
10.1097/00003072-200203000-00007
I-123 MIBG Imaging and Intraoperative Localization of Metastatic Pheochromocytoma: A Case Report
T. Buhl (2002)
10.1016/j.eururo.2011.03.046
Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique.
Kevin P. Asher (2011)
10.2967/jnumed.110.075226
Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
Y. Menda (2010)
10.1007/s12672-013-0133-2
Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma
A. Tanabe (2013)
10.1016/j.clon.2011.12.003
Radionuclide therapy in neuroendocrine tumours: a systematic review.
K.Y. Gulenchyn (2012)
10.7326/0003-4819-70-5-1061_1
Inhibition of insulin secretion by catecholamines in pheochromocytoma.
John A. Colwell (1969)
10.1111/j.1751-7176.2008.00046.x
Cyclic rapid fluctuation of hypertension and hypotension in pheochromocytoma.
Costin N Ionescu (2008)
10.1200/JCO.2005.03.1484
Genetic testing in pheochromocytoma or functional paraganglioma.
L. Amar (2005)
10.1097/00000658-199906000-00001
Clinical experience over 48 years with pheochromocytoma.
R. Goldstein (1999)
10.1007/s00259-010-1545-7
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging
E. Bombardieri (2010)
10.1136/bmj.300.6724.614-a
Hypertensive crisis precipitated by a monoamine oxidase inhibitor in a patient with phaeochromocytoma.
R. F. Cook (1990)
10.1016/j.ijsu.2015.12.042
Minimally invasive approach for adrenal lesions: Systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications.
G. Conzo (2016)
10.1111/j.1464-410X.2010.09568.x
Outcomes and timing for intervention of partial adrenalectomy in patients with a solitary adrenal remnant and history of bilateral phaeochromocytomas
Thomas Sanford (2011)
10.1016/S0039-6060(96)80056-0
Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma.
J. Lee (1996)
10.1016/0046-8177(90)90155-X
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features.
R. I. Linnoila (1990)
10.1007/S12022-003-0012-4
Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor
G. Eisenhofer (2003)
10.1016/j.jvir.2009.07.031
Radiofrequency ablation of metastatic pheochromocytoma.
A. Venkatesan (2009)
10.1016/j.bmcl.2015.08.087
Progress in the development of fatty acid synthase inhibitors as anticancer targets.
G. E. Mullen (2015)
10.1093/jnci/djs188
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
H. Timmers (2012)
10.1111/j.1365-2265.2008.03496.x
Use of 6‐[18F]‐fluorodopamine positron emission tomography (PET) as first‐line investigation for the diagnosis and localization of non‐metastatic and metastatic phaeochromocytoma (PHEO)
H. Timmers (2009)
10.1210/jc.2009-1054
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Helle-Brit Fiebrich (2009)
10.1080/00313020802579284
Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma
P. Hickman (2009)
10.1210/JCEM.86.2.7194
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
G. Kaltsas (2001)
10.3390/ijms160511055
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
C. R. Justus (2015)
10.1067/j.cpsurg.2013.12.001
Diagnosis and management of pheochromocytoma.
R. Hodin (2014)
10.1016/j.amjoto.2016.01.002
Initial radiographic tumor control is similar following single or multi-fractionated stereotactic radiosurgery for jugular paragangliomas.
Daniel Schuster (2016)
10.1155/2015/690492
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
D. Cervantes-Madrid (2015)
10.1023/A:1022981801344
Pheochromocytoma as an Endocrine Emergency
F. M. Brouwers (2004)
10.7861/clinmedicine.14-4-440
Phaeochromocytoma and paraganglioma: next-generation sequencing and evolving Mendelian syndromes.
E. Maher (2014)
10.1158/1078-0432.CCR-16-0606
Pheochromocytoma: The First Metabolic Endocrine Cancer
I. Jochmanová (2016)
10.1016/S0030-6665(05)70356-X
Glomus tympanicum and glomus jugulare tumors.
C. Jackson (2001)
10.1016/j.jamcollsurg.2012.10.012
Long-term outcomes of surgical treatment for hereditary pheochromocytoma.
E. Grubbs (2013)
10.1677/ERC-10-0211
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
G. Eisenhofer (2011)
10.1007/BF03348026
The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients
K. Loh (1997)
10.7759/cureus.447
Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery
Claudia Arnas-Leon (2016)
10.1002/pbc.22006
Treatment of disseminated paraganglioma with gemcitabine and docetaxel.
Jaume Mora (2009)
10.1001/JAMA.287.11.1427
Biochemical diagnosis of pheochromocytoma: which test is best?
J. Lenders (2002)
10.1097/00006231-199207000-00006
A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).
K. Solanki (1992)
10.1016/j.juro.2010.06.102
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup.
J. Benhammou (2010)
10.1038/sj.bjc.6605007
De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
T. Mashima (2009)
10.1056/NEJMC1101502
Drugs and Pheochromocytoma — Don't Be Fooled by Every Elevated Metanephrine
N. Neary (2011)
10.1148/RADIOLOGY.212.1.R99JL3035
Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
B. Shulkin (1999)
10.2967/jnumed.107.042721
The Effects of Carbidopa on Uptake of 6-18F-Fluoro-l-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma
H. Timmers (2007)
10.1210/JC.2005-2668
Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma.
J. Boyle (2007)
10.2174/157339910793360860
Glucose intolerance and diabetes mellitus in endocrine disorders - two case reports and a review.
Mohamed A. Adlan (2010)
10.4293/JSLS.2014.00218
Single-Port Robotic-Assisted Adrenalectomy: Feasibility, Safety, and Cost-Effectiveness
Arman Arghami (2015)
10.1016/S1043-2760(01)00492-1
Radioisotope diagnosis and therapy of malignant pheochromocytoma
B. Shapiro (2001)
10.1056/NEJM199906173402404
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
G. Eisenhofer (1999)
10.1089/089277904773582859
Laparoscopic adrenalectomy for pheochromocytoma: comparison with conventional open adrenalectomy.
H. H. Kim (2004)
10.1210/JC.2004-1398
Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.
L. Amar (2005)
10.1055/s-0029-1231025
Treatment of malignant pheochromocytoma.
R. Adjallé (2009)
10.1210/ER.2002-0013
Pheochromocytoma: state-of-the-art and future prospects.
E. Bravo (2003)
10.1200/JCO.2016.34.15_SUPPL.2506
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
Kevin D. Courtney (2016)
10.1097/00000539-200211000-00024
An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient.
Toshitaka Minami (2002)
10.1055/s-0032-1308992
External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Lauren Fishbein (2012)
10.1093/jnci/djt201
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
I. Jochmanová (2013)
10.1530/EJE-11-0497
The genetics of phaeochromocytoma: using clinical features to guide genetic testing.
M. Jafri (2012)
10.1007/s00423-011-0851-2
Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas
P. Alesina (2011)
10.1515/hsz-2013-0271
Citrate--new functions for an old metabolite.
V. Iacobazzi (2014)
10.1038/ng.861
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
I. Comino-Méndez (2011)
10.1016/J.ECL.2006.09.014
Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma.
F. M. Brouwers (2006)
10.1007/s002800051013
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma)
C. F. Kruijtzer (2000)
10.1016/B978-0-323-18907-1.00110-4
Chapter 110 – Pheochromocytoma
Karel Pacak (2016)
10.1038/ncpendmet0396
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
K. Pacak (2007)
10.1016/j.cpet.2013.08.007
68Ga-DOTA-peptides in the diagnosis of NET.
V. Ambrosini (2014)
10.1002/cncr.24796
177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
M. Garkavij (2010)
10.1002/cncr.26577
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas
M. Ayala-Ramirez (2012)
10.1210/jc.2008-1972
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
C. Jiménez (2009)
10.1007/s00259-011-1962-2
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification
A. Kroiss (2011)
10.1530/EJE.1.02097
Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass.
N. Unger (2006)
10.1016/0002-9343(90)90233-4
Epinephrine-producing pheochromocytoma with hypertensive crisis after corticotropin injection.
T. Jan (1990)
10.1373/clinchem.2010.153320
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
G. Eisenhofer (2011)
10.1210/JC.2006-0423
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.
F. M. Brouwers (2006)
10.1016/S0079-6123(10)82015-1
Pheochromocytoma and paraganglioma.
V. Kantorovich (2010)
10.1016/J.BEEM.2006.07.005
Genetic basis of phaeochromocytoma and paraganglioma.
D. Benn (2006)
10.1097/01.HJH.0000251887.01885.54
Pheochromocytoma: presentation, diagnosis and treatment.
N. Reisch (2006)
10.1016/j.amjsurg.2014.11.012
Effectiveness and safety of laparoscopic adrenalectomy of large pheochromocytoma: a prospective, nonrandomized, controlled study.
Weigang Wang (2015)
10.5152/dir.2013.048
Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Niraj Naswa (2013)
10.1172/JCI110306
Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle.
J. Chiasson (1981)
10.1530/EJE-14-0113
Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma.
E. Baudin (2014)
10.1111/j.1748-1716.2007.01809.x
Diseases of the adrenal medulla
M. Fung (2008)
Use of labetalol during anesthesia for pheochromocytoma removal.
M. Van Stratum (1983)
10.1007/s00259-012-2215-8
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma
D. Taïeb (2012)
10.1200/JCO.2010.31.7131
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas.
D. Cecchin (2011)
10.1210/jc.2011-0333
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
Kathryn S. King (2011)
10.1210/JC.2002-021913
Editorial: biochemical diagnosis of pheochromocytoma--is it time to switch to plasma-free metanephrines?
G. Eisenhofer (2003)
10.1210/jc.2008-1836
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Anthony M Joshua (2009)
10.1210/JC.2006-1544
Clinical review: Current treatment of malignant pheochromocytoma.
T. Scholz (2007)
10.4103/0970-9185.161665
Pheochromocytoma resection: Current concepts in anesthetic management
H. Ramakrishna (2015)
10.1055/s-0031-1299707
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
P. Plouin (2012)
10.1046/J.1365-2168.1999.00974.X
Adrenal‐sparing surgery for phaeochromocytoma
H. Neumann (1999)
10.1210/JCEM.84.8.5872
Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma.
H. Neumann (1999)
10.1097/00000542-197904000-00019
Innovar-induced hypertensive crises in patients with pheochromocytoma.
D. Bittar (1979)
10.1038/jhh.2012.20
An update on the genetics of pheochromocytoma
D. Karásek (2013)
10.1002/jso.23196
Radionuclide therapy of adrenal tumors.
Jorge A. Carrasquillo (2012)
10.1007/BF01536169
Inadvertent diagnosis of pheochromocytoma after endoscopic premedication
Maurice Barancik (2005)
10.1007/s00330-011-2289-x
Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study
Niraj Naswa (2011)
10.1007/s00259-016-3357-x
PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma
Ingo Janssen (2016)
10.1001/ARCHINTE.160.19.2957
Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma.
W. Raber (2000)
10.1677/ERC.1.00829
Malignant pheochromocytoma: current status and initiatives for future progress.
G. Eisenhofer (2004)
10.1111/J.1749-6632.2002.TB04423.X
Diagnostic Localization of Pheochromocytoma
K. Pacak (2002)
10.1210/jcem.81.4.8636337
Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma.
R. Peaston (1996)
10.1016/j.juro.2010.03.052
Partial adrenalectomy: underused first line therapy for small adrenal tumors.
D. Kaye (2010)
10.1055/s-0029-1220687
Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
M. Druce (2009)
10.7326/0003-4819-134-4-200102200-00016
Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma
K. Pacak (2001)
10.1161/01.HYP.38.1.6
6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma
K. Pacak (2001)
Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?
A. Stefanelli (2013)
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
M. van Essen (2006)
10.1053/j.semnuclmed.2016.01.011
I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Jorge A. Carrasquillo (2016)
Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis.
A. V. D. van der Horst-Schrivers (2006)
10.1053/j.jvca.2017.02.023
Perioperative management of pheochromocytoma.
M. A. Kinney (2002)
10.1038/sj.onc.1209597
Glycolysis inhibition for anticancer treatment
H. Pelicano (2006)
10.1530/EJE.0.1500681
Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients.
J. Baguet (2004)
10.1007/s12672-015-0231-4
Pheochromocytoma: Gasping for Air
I. Jochmanová (2015)
10.1002/jso.23162
Molecular imaging of adrenal neoplasms.
Clara C. Chen (2012)
10.1373/clinchem.2014.224832
Laboratory evaluation of pheochromocytoma and paraganglioma.
G. Eisenhofer (2014)
10.4103/0972-3919.116801
Usefulness of single photon emission computed tomography (SPECT)/computed tomography and radioguided surgery in a patient with recurrent pheochromocytoma
J. Uña-Gorospe (2013)
10.1055/s-0032-1311637
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
S. Zovato (2012)
10.2967/jnumed.112.115485
68Ga-DOTANOC PET/CT for Baseline Evaluation of Patients with Head and Neck Paraganglioma
P. Sharma (2013)
10.1002/1097-0142(19850301)55:5<1099::AID-CNCR2820550527>3.0.CO;2-3
Vasoactive intestinal polypeptide‐, somatostatin‐, and calcitonin‐producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings
G. Viale (1985)
10.1016/j.ccr.2008.05.005
Tumor cell metabolism: cancer's Achilles' heel.
G. Kroemer (2008)
10.1016/j.ando.2010.04.004
Chromogranin A assay in clinical practice.
M. D'herbomez (2010)
10.1038/nrd3504
Targeting cancer metabolism: a therapeutic window opens
M. V. Heiden (2011)
10.1097/00004872-200309000-00020
Diabetes as a marker of pheochromocytoma in hypertensive patients
A. La Batide-Alanore (2003)
10.1016/j.ejca.2011.07.016
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
G. Eisenhofer (2012)
10.1210/JC.2002-021251
A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.
A. Sawka (2003)
10.1007/s00259-012-2309-3
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT
A. Kroiss (2012)
10.1023/A:1011572617314
Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma
G. Eisenhofer (2004)
10.3892/OR.9.6.1225
Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging.
T. Nakatani (2002)
10.1210/jc.2008-2419
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas.
M. Mannelli (2009)
10.1056/NEJMOA020152
Germ-line mutations in nonsyndromic pheochromocytoma.
H. Neumann (2002)
10.1007/s12020-009-9219-6
Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma
J. He (2009)
10.1210/JC.2002-030005
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.
G. Eisenhofer (2003)
10.1210/JC.2003-031091
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma.
I. Ilias (2004)
10.1111/j.1365-2265.2006.02591.x
The role of chromogranin A in the management of patients with phaeochromocytoma
E. Grossrubatscher (2006)
10.2174/1389200216666150602145145
Glucose Addiction in Cancer Therapy: Advances and Drawbacks.
Sara Granja (2015)
10.1152/ajpendo.00156.2012
Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Yuichi Aita (2012)
10.7326/0003-4819-109-4-267
Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.
S. D. Averbuch (1988)
10.1007/s10689-013-9639-6
Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families
K. Jasperson (2013)
10.1530/EJE.0.1410619
Pheochromocytoma in Italy: a multicentric retrospective study.
M. Mannelli (1999)
10.1159/000173958
Diagnosis and management of pheochromocytoma.
R. Gifford (1985)
10.1097/MPA.0b013e3181ebb4f0
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer
H. Chen (2010)
10.1373/CLINCHEM.2006.076489
Is supine rest necessary before blood sampling for plasma metanephrines?
J. Lenders (2007)
10.1055/s-0029-1224135
Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report.
E. Bravo (2009)
10.1016/j.maturitas.2013.12.009
Pheochromocytoma: a review.
A. Tsirlin (2014)
10.1210/jc.2010-1946
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
M. Ayala-Ramirez (2011)
Laparoscopic treatment of pheochromocytomas smaller or larger than 6 cm. A clinical retrospective study on 44 patients. Laparoscopic adrenalectomy for pheochromocytoma.
Giovanni Conzo (2013)
10.1111/j.1365-2265.1995.tb01877.x
Short‐term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo‐controlled trial
P. Plouin (1995)
10.1186/s12957-016-0779-7
An intermediate term benefits and complications of gamma knife surgery in management of glomus jugulare tumor
Raef F. A. Hafez (2016)
ACTH-producing pheochromocytoma.
M. Berenyi (1977)
10.1055/S-2004-819319
Efficacy of Octreotide in combination with MIBG-radiotherapy in patients with advanced pheochromocytoma
J. Mundschenk (2004)
10.1016/j.ijrobp.2011.05.006
Radiosurgery of glomus jugulare tumors: a meta-analysis.
Z. Guss (2011)
10.1055/S-2007-993135
Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
S. Cleary (2007)
10.1152/ajpendo.1983.245.6.E616
Direct alpha-adrenergic stimulation of hepatic glucose production in human subjects.
S. Rosen (1983)
10.1210/jc.2008-2697
Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
K. Nomura (2009)
10.1038/onc.2015.447
Glutaminolysis as a target for cancer therapy
L. Jin (2016)
10.1007/s00259-013-2548-y
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma
A. Kroiss (2013)
10.1159/000074659
Biochemical diagnosis of pheochromocytoma.
G. Eisenhofer (2004)
10.1210/jc.2012-2356
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
M. Ayala-Ramirez (2012)
10.1097/MED.0b013e32835fcc45
Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options
A. Vicha (2013)
10.1016/S0090-4295(98)00612-8
Pheochromocytomas: can malignant potential be predicted?
H. John (1999)
10.1016/j.jvir.2011.06.016
Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy.
J. Mcbride (2011)
10.1111/j.1365-2265.2009.03648.x
New imaging approaches to phaeochromocytomas and paragangliomas
B. Havekes (2010)
10.1515/cclm.2011.742
Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal
F. Mullins (2011)
10.1016/j.currproblcancer.2014.01.001
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.
Victoria L Martucci (2014)
10.1038/nrendo.2014.188
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
J. Favier (2015)
10.1111/eci.12495
Metastatic pheochromocytoma and paraganglioma
A. Angelousi (2015)
10.2169/INTERNALMEDICINE.44.222
Pheochromocytoma presenting as recurrent hypotension and syncope.
T. Ueda (2005)
10.1111/j.1365-2265.1995.tb00531.x
Investigation of phaeochromocytoma.
P. Bouloux (1995)
10.1200/JCO.2006.09.6297
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
H. Timmers (2007)
10.1055/s-0031-1299712
Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
H. Timmers (2012)
10.1016/j.neo.2016.06.001
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma☆
Matthew H. Wong (2016)
10.1007/s12020-013-0007-y
Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features
A. Mazza (2013)
10.1016/j.ccr.2013.04.018
SDH mutations establish a hypermethylator phenotype in paraganglioma.
E. Letouzé (2013)
10.1210/jc.2009-1248
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
H. Timmers (2009)
10.1136/heartjnl-2013-304073
Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma
A. Giavarini (2013)
10.1111/cen.12071
Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma
S. R. Galan (2013)
10.1245/s10434-013-3134-z
Robotic Versus Laparoscopic Adrenalectomy for Pheochromocytoma
S. Aliyev (2013)
10.1210/JCEM.86.2.7238
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
E. van der Harst (2001)
10.1152/ajpendo.00035.2011
Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
Yuria Saito (2012)
10.3389/fonc.2014.00166
External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
Jennifer Vogel (2014)
10.1007/s00464-012-2451-9
Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma
Trudie A. Goers (2012)
10.1016/0735-1097(93)90786-Z
Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans.
D. Goldstein (1993)
10.1097/COC.0b013e318187dd94
Paraganglioma of the Head and Neck: Long-term Local Control with Radiotherapy
J. Chino (2009)
10.1016/j.biopha.2008.01.010
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
S. Fanti (2008)
10.1159/000348429
Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
Tiziana Prochilo (2013)
10.1007/s00259-012-2119-7
A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma
James Maurice (2012)
10.1016/j.jamcollsurg.2013.04.027
Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?
R. Ellis (2013)
10.1093/JNCI/93.8.648
Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma.
K. Pacak (2001)
10.1111/J.1445-5994.2000.TB04358.X
Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland.
A. McNeil (2000)
10.2967/jnumed.115.161018
68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI
Ingo Janssen (2016)
10.1007/s11307-010-0396-8
68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours
M. Naji (2010)
10.1258/acb.2012.012112
Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma
M. Peitzsch (2013)
10.3390/molecules21070876
Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors
Shuang Cao (2016)
10.3949/ccjm.60.5.365
Pheochromocytoma: current diagnosis and management.
Manger Wm (1993)
10.1042/cs0580349
Haemodynamics in patients with phaeochromocytoma.
J. Levenson (1980)
10.1016/j.jamcollsurg.2012.10.002
Management of exclusively dopamine-secreting abdominal pheochromocytomas.
É. Poirier (2013)
10.1210/jc.2014-1498
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
J. Lenders (2014)
10.1111/j.1471-4159.1987.tb03395.x
Chromogranin A synthesis and secretion in chromaffin cells.
L. Eiden (1987)
10.1210/JC.2007-1720
Preoperative management of the pheochromocytoma patient.
K. Pacak (2007)
Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison.
S. Maurea (1996)
10.1016/0002-9343(87)90912-0
Localization of ectopic pheochromocytomas by magnetic resonance imaging.
J. F. Schmedtje (1987)
10.1210/edrv-15-3-356
Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.
E. Bravo (1994)
10.1097/HJH.0b013e32813aeb5a
Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients
J. Václavík (2007)
10.1530/EJE.0.1470085
The value of plasma markers for the clinical behaviour of phaeochromocytomas.
E. van der Harst (2002)
10.1148/RADIOL.2222010622
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..
S. Hoegerle (2002)
10.1159/000185503
Features of malignancy in a benign pheochromocytoma.
M. Stumvoll (1997)
10.1210/jc.2011-3342
11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma: a single center experience over 11 years.
S. Yamamoto (2012)



Semantic Scholar Logo Some data provided by SemanticScholar